Home/Investors/F-Prime Capital

F-Prime Capital

Biotech Investor · 2 portfolio companies

Portfolio

2

Combined Value

$909.5M

Focus Areas

6

Top Stage

Phase 1/2

Investment Focus

Oncology Inflammatory Diseases Genetic Disorders Neuroscience Psychiatry Neurodegenerative Diseases

Portfolio Companies

Company	Stage	Valuation	Focus
enGene	Phase 1/2	$483.0M	Oncology, Inflammatory Diseases
Neumora Therapeutics	Phase 3	$426.5M	Neuroscience, Psychiatry

Frequent Co-Investors

Arch Venture Partners1 shared Forbion1 shared GV (Google Ventures)1 shared Catalio Capital Management1 shared Omega Funds1 shared Amgen1 shared Invus1 shared Altitude Life Science Ventures1 shared